Efficacy and safety of palbociclib in patients with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer with preexisting conditions:...

por Gelmon, Karen, Walshe, Janice M., Mahtani, Reshma, Joy, Anil A., Karuturi, Meghan, Neven, Patrick, Lu, Dongrui Ray, Kim, Sindy, Schnell, Patrick, Bananis, Eustratios, Schwartzberg, Lee
Publicado 2021

Real-World Tumor Response of Palbociclib in Combination With an Aromatase Inhibitor as First-Line Therapy in Pre/Perimenopausal Women With Metastatic Breast Cancer

por DeMichele, Angela, Robert, Nicholas, Chen, Connie, Kim, Sindy, Zhang, Zhe, Lu, Dongrui Ray, Aguilar, Kathleen M., Wang, Yunfei, Li, Benjamin, Schneeweiss, Sebastian, Rassen, Jeremy A., Gaffney, Michael, McRoy, Lynn
Publicado 2023

Palbociclib plus letrozole as treatment for postmenopausal women with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer for whom le...

por Loi, Sherene, Karapetis, Christos S., McCarthy, Nicole, Oakman, Catherine, Redfern, Andrew, White, Michelle, Khasraw, Mustafa, Doval, Dinesh Chandra, Gore, Vinod, Alam, Mahmood, Binko, Justin, Lu, Dongrui Ray, Kim, Sindy, Boyle, Frances
Publicado 2021

Phase II study of sunitinib as second-line treatment for advanced gastric cancer

por Bang, Yung-Jue, Kang, Yoon-Koo, Kang, Won K., Boku, Narikazu, Chung, Hyun C., Chen, Jen-Shi, Doi, Toshihiko, Sun, Yan, Shen, Lin, Qin, Shukui, Ng, Wai-Tong, Tursi, Jennifer M., Lechuga, Maria J., Lu, Dongrui Ray, Ruiz-Garcia, Ana, Sobrero, Alberto
Publicado 2010